Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

These lawsuits, filed across 30 countries, underscore the competitive nature of mRNA technologies and potential financial implications, possibly influencing Moderna's stock, which rose 15% last week.

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

These lawsuits, filed across 30 countries, underscore the competitive nature of mRNA technologies and potential financial implications, possibly influencing Moderna's stock, which rose 15% last week.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...